Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795717 · ClinicalTrials.gov registry record · Phase 4
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
A Phase 4 study, sponsored by Tufts University.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT00795717 is a Phase 4 study that has completed, run by Tufts University. The registered enrollment target is 41 participants.
The verdict
NCT00795717, a Phase 4 study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL), and an improvement of endothelial dysfunction.
Interventions
- DRUG Placebo
- DRUG Lovaza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795717
The ClinicalTrials.gov registry entry for NCT00795717 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00795717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795717 about?
NCT00795717 is a clinical study titled "Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial". The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL), and an improvement of endothelial dysfunction.
What is the current status of trial NCT00795717?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2008-07. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00795717?
The interventions under investigation include: Placebo (DRUG), Lovaza (DRUG).
Who is sponsoring clinical trial NCT00795717?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.